Promising drug for rare Skin-Hardening disease fails to complete trial
NCT ID NCT04781543
First seen Mar 28, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study tested a drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare condition that causes skin thickening and can affect the lungs. Participants took either a low dose, a high dose, or a placebo for 52 weeks. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital de La Santa Creu i Sant Pau
Barcelona, 08025, Spain
-
Institute for Treatment and Rehabilitation Niska Banja
Niška Banja, 708120, Serbia
-
Institute of Rheumatology - PPDS
Belgrade, 11000, Serbia
-
Military Medical Academy
Belgrade, 11000, Serbia
Conditions
Explore the condition pages connected to this study.